drugset / Trial / NCT01648699
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.
Timeline
- Start
- 2010-04
- Primary completion
- 2010-09
- Completion
- 2010-09
Outcome
Outcome not reported
Stopped: “the study was stopped due to non-availability of 4mg”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 8 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 12 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 16 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 20 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 24 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 32 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 36 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 40 mg | Oral |
Indications
No indication recorded.